MedTrace Logo

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.

NCT03878433 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-14

No results posted yet for this study

Summary

Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to decrease melasma severity.

Conditions

  • Melasma

Interventions

DRUG

Glisodin

500 mg/day between 12 weeks

OTHER

placebo

Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    lead OTHER

Principal Investigators

  • Passeron Thierry, PhD · Dermatologie, CHU de Nice

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2020-01-01
Completion
2020-07-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03878433 on ClinicalTrials.gov